{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreic4ammjqp5bour5zfwkcd62bonmgsglbe2hjv3xlp3nvdfphifgva",
    "uri": "at://did:plc:ox2kiwcr2xmn32p25g472pp7/app.bsky.feed.post/3mhc6xizqsq42"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiepxwl4khtmnzaywsg6kdokgsea4hbjee4gd63r5jfv5zlwmjwtty"
    },
    "mimeType": "image/webp",
    "size": 38422
  },
  "path": "/releases/2026/03/260317015933.htm",
  "publishedAt": "2026-03-17T01:59:33.000Z",
  "site": "https://www.sciencedaily.com",
  "textContent": "mRNA vaccines saved millions of lives during COVID-19 but have limitations like waning immunity and complex production. Scientists are now testing a new platform called DoriVac, which uses folded DNA nanostructures to better control how the immune system responds. In early studies, it produced strong antibody and T cell responses in both mice and human models. Researchers say it could lead to more stable, easier-to-manufacture vaccines for diseases like COVID-19, HIV, and Ebola.",
  "title": "DNA origami vaccines could be the next leap beyond mRNA"
}